Allarity Therapeutics (ALLR) Other Accumulated Expenses (2020 - 2026)

Allarity Therapeutics (ALLR) has 7 years of Other Accumulated Expenses data on file, last reported at $346000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 6.99% year-over-year to $346000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $346000.0 (down 6.99% YoY) and the FY2025 annual result came in at $146000.0, down 46.72% from the prior year.
• Other Accumulated Expenses rose to $346000.0 in Q1 2026, from $146000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.6 million in Q3 2022 to a low of $61000.0 in Q4 2023.
• A 5-year average of $394500.0 and a median of $261000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses soared 349.18% — and 2025, when it slumped 46.72%.
• Tracing ALLR's Other Accumulated Expenses over 5 years: stood at $1.6 million in 2022, then slumped by 96.29% to $61000.0 in 2023, then soared by 349.18% to $274000.0 in 2024, then tumbled by 46.72% to $146000.0 in 2025, then surged by 136.99% to $346000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $346000.0 (Q1 2026), $146000.0 (Q4 2025), and $604000.0 (Q3 2025), per Business Quant data.